Mar. 14, 2014, 8:13 AM
- Johnson and Johnson (JNJ) faces 20,000 product liability lawsuits relating to Ethicon's transvaginal mesh. The product was used to treat pelvic organ prolapse. It withdrew the product from the market in 2012 citing business reasons, but some recipients of the device complained of pain due to its shrinkage or erosion from its original placement.
- Documents provided by J&J in the discovery process suggest that a company-paid physician consultant sought to change the language of the treatment guidelines published by a medical society in 2007.
- The company also attempted to change the language of a research paper published in the New England Journal of Medicine in 2011. The journal's editors are currently fighting a subpoena to testify in the case.
- The firm engaged the MD as a consultant for 10 years paying him ~$800,000.
Mar. 12, 2014, 11:50 AM
- California Technology Assessment Forum members give a "low value" rating to Gilead's (GILD) pricey hepatitis C treatment Sovaldi citing its high cost. The vote is non-binding but could influence coverage decisions by payers.
- The panel agrees that not all hep C patients require the most expensive drugs. If California treated every patient with liver damage it would cost the state over $6B.
- Sovaldi's treatment regimen costs $84,000 compared to $66,000 for J&J's (JNJ) Olysio.
Mar. 11, 2014, 9:24 AM
- GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and TPI Enterprises want the government of Australia to let them grow poppies on the country's mainland, due to a shortage of opium for pain killers and amid soaring demand.
- Australia only allows poppy growing in Tasmania, which is responsible for around half of the world's supply of opiate-based pain relief. Recent drought and storms in Tasmania have meant that drug firms can't get enough crops.
Mar. 10, 2014, 10:00 AM
- The WSJ profiles "pharmaceutical scouts," who, like talent-spotters in baseball "trying to pick tomorrow's big-leaguers from farm teams," search outside their companies to find drug candidates that have the potential to become blockbusters.
- In 2011, for instance, Johnson & Johnson's (JNJ) Peter Lebowitz helped his company beat competitors such as Novartis (NVS) to buy the rights to a blood-cancer drug from Pharmacyclics (PCYC) called Imbruvica.
- The treatment was eventually approved in November for a rare lymphoma and for chronic lymphocytic leukemia in February. J.P. Morgan forecasts Imbruvica will generate $1.3B in revenue for J&J in 2017.
- Half of J&J's drug pipeline is from outside the company, up from 20% in 2002.
- Other related tickers: MRK, RHHBY, BMY, SNY, CELG, GSK
Mar. 10, 2014, 9:05 AM
- Johnson & Johnson (JNJ) has agreed to sell the global rights to its K-Y brand of intimate lubricants to Reckitt Benckiser (RBGLY).
- While the price of the deal wasn't provided, Reckitt did say that K-Y had 2013 sales of over $100M, the majority of which was generated in the U.S. Canada and Brazil.
- K-Y adds to Reckitt's Durex brand.
- The transaction doesn't include staff or fixed assets. (PR)
Feb. 14, 2014, 8:55 AM
- Johnson & Johnson's (JNJ) Janssen unit says the FDA rejected its supplemental new drug application to use the oral anticoagulant Xarelto to reduce the risk of heart attacks or strokes in patients with acute coronary syndrome.
- An application seeking to gain approval to use the drug in the same population to reduce the risk of stent thrombosis also was rejected.
- Xarelto has been approved for several indications relating to reducing the risk of blood clots.
Feb. 10, 2014, 7:56 AM
- Addex Therapeutics' (ADDXF) ADX71149 treatment for anxious depression was not more effective than a placebo in a Phase IIa trial.
- The results don't "support the further development of ADX71149 in anxious depression," Addex says, although the exploration of the drug for other purposes "remains of potential interest."
- Johnson & Johnson (JNJ) unit Janssen conducted the trial.
- The failure is a major blow, as anxious depression is a leading cause of disability worldwide.
- Addex shares are -27% in Zurich. (PR)
Feb. 4, 2014, 8:28 AM
- Ten major pharmaceuticals companies are getting together with the National Institutes of Health and other organizations in a five-year partnership that will look to understand the science behind Alzheimer's, Type 2 diabetes, rheumatoid arthritis and lupus.
- In an unusual move, the normally secretive participants will share scientists, tissue, blood samples and data, with the aim being to identify targets for new drugs.
- The firms involved include Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), GlaxoSmithKline (GSK), Takeda (TKPHF) and Sanofi (SNY).
- Those that haven't joined include Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
Jan. 30, 2014, 9:31 AM
- Johnson & Johnson (JNJ) has become the latest major pharmaceutical firm to say that it will make more data from its clinical trials available to researchers.
- JNJ has signed an agreement with Yale University to share information about hundreds of drugs and other products.
- Yale will vet requests from researchers without input from J&J.
- Part of the idea is to increase the credibility of the data. "The medical scientific community and population at large want to have more transparency on what we do," says J&J's Paul Stoffels. "To get really credible, we took the leap."
- Other big pharma companies to pledge to release data in the past year include GSK and Roche. (PR)
Jan. 28, 2014, 5:15 PM
- Medivation (MDVN) +8.2% AH after its Xtandi drug for advanced prostate cancer was found to significantly delay progression of the disease and extend survival in a large, late stage study of patients who had not yet received chemotherapy.
- Xtandi (enzalutamide) already is approved to treat patients whose prostate cancer has spread and who had previously been treated with chemotherapy; approval for use prior to chemo could greatly expand the available patient population, significantly boost sales, and enable the drug to compete with Johnson & Johnson's (JNJ) Zytiga.
- Sanford Bernstein says annual Xtandi sales eventually could exceed $3B with a pre-chemo approval.
Jan. 21, 2014, 11:36 AM
- Lower today amid a disappointing full year outlook, Johnson & Johnson (JNJ -1.7%) is a buy on the dip says RBC's Glen Novarro. The weak early-year guidance sets management up to beat and raise throughout 2014. "We continue to recommend [J&J] based on strong growth in pharmaceuticals and under-appreciated operating margins."
- Earlier: Management guides to full-year EPS of $5.75-$5.85 vs. consensus $5.86.
Jan. 21, 2014, 8:01 AM
- J&J (JNJ +0.85%) Q4 net profit $3.52B vs $2.57B a year earlier.
- Domestic sales +7.4%, international sales +2.4%
- 2013 results were "led by the outstanding performance in our pharmaceutical business, the strength of key brands in our U.S. OTC and other consumer businesses, and continued progress in integrating Synthes into our Medical Devices and Diagnostics business," says J&J CEO Alex Gorsky.
- J&J expects 2014 EPS of $5.75-5.85 vs consensus of $5.85. (PR)
Jan. 21, 2014, 7:46 AM| 10 Comments
Jan. 21, 2014, 12:05 AM
Jan. 20, 2014, 5:30 PM
Jan. 16, 2014, 4:06 PM
JNJ vs. ETF Alternatives
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.
Other News & PR